Managing Multiple Sclerosis: A Guide for Specialty Pharmacy Professionals and other Care Managers Web Activity

Release Date: July 8, 2019
Expiration Date: January 31, 2021
Estimated Time to Complete Activity: 1 hour
Compatible with all modern browsers and mobile devices

EXPERT FACULTY


	Edmund Pezalla, MD, MPH CEO Enlightenment Bioconsult, LLC Click here for biography

	Harold Moses, Jr., MD Associate Professor of Neurology Neuroimmunology Division Vanderbilt University Click here for biography

TARGET AUDIENCE

Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for patients with multiple sclerosis (MS) including: physicians, pharmacists, and nurses

STATEMENT OF NEED/PROGRAM OVERVIEW

Multiple sclerosis (MS) is a chronic immune-mediated degenerative disorder of the central nervous system (CNS) which affects an estimated 400,000 individuals in the United States. Onset typically occurs between the ages of 20 and 40 years; in fact, MS is the leading cause of non-traumatic disability in young adults. Women are affected approximately twice as often as men. The clinical and economic burden of MS is significant due to its extensive morbidity and need for chronic treatment. The expert faculty will discuss best practices to deliver quality care to MS patients and improve quality of life over the course of the disease.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

Review the safety, efficacy, and other attributes of emerging MS therapies
Discuss recent insights into cost offsets associated with new and emerging MS therapies
Employ specialty pharmacy management and benefit design strategies for MS therapies to promote appropriate prescribing
Analyze care pathways and their application to manage economic outcomes in MS

ACCREDITATION

Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources, Inc. (MER) and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

Accreditation Statement
Medical Education Resources, Inc. (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
MER designates this continuing education activity for 1.0 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education. Universal Activity Number 0816-9999-19-137-H01-P.

Nursing Continuing Education
Accreditation Statement
Medical Education Resources, Inc. (MER) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. MER is accredited as a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Credit Designation
This CE activity provides 1.0 contact hour of continuing nursing education.

DISCLOSURE OF CONFLICTS OF INTEREST
It is the policy of Medical Education Resources, Inc. (MER) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

*Name of Faculty or Presenter*	*Reported Financial Relationship*
Edmund Pezalla, MD, MPH	Consulting Fees (eg, Advisory Boards): Biomarin
Harold Moses, Jr., MD	Grants/Research Support: Medday, ATARA, Novartis and MediciNova Consulting Fees (eg, Advisory Boards): Biogen, Genzyme, Genetech, Celgene, EMD Serono, Novartis Speakers’ Bureau: Biogen, EMD Serono, Novartis, Genzyme

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

*Name of Planner or Manager*	*Reported Financial Relationship*
Impact Education, LLC Content Managers	No financial interest/relationships relating to the topic of this activity
MER Content Managers	No financial interest/relationships relating to the topic of this activity

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Inc., Impact Education, LLC, and/or Sanofi Genzyme. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medical Education Resources, Inc., Impact Education, LLC, and/or Sanofi Genzyme. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Method of Participation and Request for Credit
There are no fees for participating and receiving CPE credit for this activity. During the period July 8, 2019 through January 31, 2021, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 70% or better; 4) and complete the evaluation form. Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.